New Boston Scientific CEO committed to having FDA warning letter lifted
This article was originally published in The Silver Sheet
Executive Summary
Ray Elliott took the reins as CEO of cardiovascular device maker Boston Scientific July 13 following the retirement of Jim Tobin. The most specific short-term priority identified by Elliott is clearing the company completely from its 2006 FDA corporate warning letter, which identified pervasive quality system and adverse event reporting deficits throughout Boston Scientific's operations ("The Silver Sheet" March 2009). The agency agreed to lift restrictions associated with the warning letter on new product approvals last October due to a finding of "substantial compliance," the company says. However, Elliott acknowledges that "we still have some work to do" to get the letter lifted, primarily in the area of adverse event reporting. Elliott - who spent a decade as chief executive at orthopedic firm Zimmer - committed himself to at least five years in the CEO post, according to Boston Scientific's June 25 filing with the Securities & Exchange Commission. Tobin, who served as CEO for a decade, will stay on as a senior adviser through Nov. 30
You may also be interested in...
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?
Thumbs Up: FDA Authorizes Weight Loss Suturing Systems From Apollo Endosurgery
People with obesity now have new tools to help them lose weight, thanks to the US agency’s de novo authorization.
FDA Slaps High Risk Class I Label On Recall Of COVID-19 Diagnostics Made In Uncontrolled Plant
More than 160,000 of the tests were recalled, including 104,900 COVID Test Kits Nonsterile and 61,500 Clean Catch Urine Kits.